Publikationen

2017

Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2017 Jun 20. doi: 10.1007/s10120-017-0737-2. [Epub ahead of print]

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Apr 27. doi: 10.1001/jamaoncol.2017.0515. [Epub ahead of print]

Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer. 2017 Apr 29;79:50-60. doi: 10.1016/j.ejca.2017.03.023. [Epub ahead of print]

Al-Batran SE, Lorenzen S. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge? Hematol Oncol Clin North Am. 2017 Jun;31(3):441-452. doi: 10.1016/j.hoc.2017.01.004. Epub 2017 Mar 29. 

zur Hausen G, Gröne J, Kaufmann D, Niehues SM, Aschenbrenner K, Stroux A, Hamm B, Kreis ME, Lauscher JC. Influence of pelvic volume on surgical outcome after low anterior resection for rectal cancer. Int J Colorectal Dis. 2017 Mar 18. doi: 10.1007/s00384-017-2793-9. [Epub ahead of print]

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncol.  2017 Mar 23. doi: 10.1001/jamaoncol.2016.5751. [Epub ahead of print]

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol. 2017 Mar 11. doi: 10.1007/s00432-017-2374-x. [Epub ahead of print] Review.

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; for FIRE-3 study investigators. Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). Int J Cancer. Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592.

Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators .A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3.

2016

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Oct 21. pii: S1470-2045(16)30531-9. doi: 10.1016/S1470-2045(16)30531-9.

Lee LD, zur Hausen G, Aschenbrenner K, Stroux A, Kreis ME, Lauscher JC. Perioperative platelet inhibition in elective inguinal hernia surgery - increased rate of postoperative bleeding and hematomas? Int Surg In-Press. doi: 10.9738/INTSURG-D-16-00041.1

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Ann Oncol. 2016 Oct 17. pii: mdw425.

Hofheinz RD, Lange C, Ecke T, Kloss S, Linsse B, Windemuth-Kieselbach C, Hammerer P, Al-BatranSE. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime study. BJU Int. 2016 Sep 12 doi: 10.1111/bju.13658. [Epub ahead of print]

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016 Aug 27. pii: S1470-2045(16)30269-8. doi: 10.1016/S1470-2045(16)30269-8. [Epub ahead of print]

Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A. [HER2 testing in gastric cancer - results of a German expert meeting]. Z Gastroenterol. 2016 Aug;54(8):791-6. doi: 10.1055/s-0042-110794. Epub 2016 Aug 16. German.

Haense N, Atmaca A, Pauligk CSteinmetz K, Marmé F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.

Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R,Lorenzen S, Moehler M, Thuss-Patience P. HER2 testing in gastric cancer : Results of a meeting of German experts. Pathologe. 2016 Jul;37(4):361-6. doi: 10.1007/s00292-016-0179-3.

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol. 2016 May 27. pii: mdw222. [Epub ahead of print]

Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, Sauer M, Al-Batran SE, Kaufmann AM, Schneider A,Jäger E, von Knebel Doeberitz M. A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus-associated cancers. Cancer. 2016 Mar 7. doi: 10.1002/cncr.29925. [Epub ahead of print]

Müller DW, Pauligk C, Al-Batran S-E. Potenzial chirurgischer Interventionen – Resektion von Primärtumor und/oder Metastasen bei metastasierten Adenokarzinomen des Magens oder des ösophagogastralen Übergangs. CONNEXI. Nr 1, 4 Jahrgang, Februar 2016.

Kaufmann D, Lauscher JC, Gröne J, zur Hausen G, Kreis ME, Hamm B, Niehues SM. CT-based measurement of the inner pelvic volume. Acta Radiologica. 2016 Mar 9. doi:10.1177/0284185116637248

Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†. Ann Oncol. 2016 Jan 7. pii: mdv625. [Epub ahead of print]

2015

Müller DW, Mönig S, Lorenz D, Homann N, Rödel C, Shah MA, Sasako M, Zander T, Pauligk C, Al-Batran S-E. Renaissance / FLOT5 – Effekt von Chemotherapie alleine vs. Chemotherapie gefolgt von operative Resektion auf Überleben und Lebensqualität bei Patienten mit limitiert-metastasierten Adenokarzinomen des Magens oder des ösophagogastralen Übergangs – eine Phase III Studie der AIO/CAO-V/CAOGI. FORUM. 2015. 30:536-537.

Goetze TO. Gallbladder carcinoma: Prognostic factors and therapeutic options World J Gastroenterol 21(43):12211-12217. Published online 2015 November 21.doi: 10.3748/wjg.v21.i43.12211.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2015 Nov 2. pii: JCO.2015.62.9170. [Epub ahead of print]

Vogel A, Kullmann F, Kunzmann V, Al-Batran SE, Oettle H, Plentz R, Siveke J, Springfeld C, Riess H. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat. 2015;38(11):596-603. doi: 10.1159/000441310. Epub 2015 Oct 20.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8.

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G,Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. J Clin Oncol. 2015 Aug 10. pii: JCO.2015.61.2887. [Epub ahead of print]

Kripp M, Al-Batran SE, Hofheinz RD. Gastric Cancer. 2016 Jan;19(1):320-1. doi: 10.1007/s10120-015-0532-x. Epub 2015 Aug 20 

Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F, Al-Batran SE, Schneeweiss A. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol. 2015 Aug 1;33(22):2444-9. doi: 10.1200/JCO.2014.60.4587. Epub 2015 Jun 29

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C; Arbeitsgemeinschaft Internistische Onkologie (AIO). The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015 Jun;26(6):1244-8. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9. 

Atmaca A, Wirtz RW, Werner D, Steinmetz K, Claas S, Brueckl WM, Jäger E, Al-Batran SE. SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer.  BMC Cancer. 2015 Apr 17;15:300. doi: 10.1186/s12885-015-1310-1

Hipp M, Pilz L, Al-Batran SE, Hautmann MG, Hofheinz RD. Workload and Quality of Life of Medical Doctors in the Field of Oncology in Germany - a Survey of the Working Group Quality of Life of the AIO for the Study Group of Internal Oncology. Oncol Res Treat. 2015;38(4):154-9. doi: 10.1159/000381074. Epub 2015 Mar 31.

Amato G, Romano G, Agrusa A, Marasa S, Cocorullo G, Gulotta G, Goetze T, Puleio R. Biologic response of inguinal hernia prosthetics: a comparative study of conventional static meshes versus 3D dynamic implants. Artif Organs. 2015 Jan;39(1):E10-23. doi: 0.1111/aor.12416.

2014

Goetze TO, Paolucci V. Influence of high- and low-volume liver surgery in gallbladder carcinoma. World J Gastroenterol. 2014 Dec 28;20(48):18445-51. doi: 0.3748/wjg.v20.i48.18445.

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2014 Dec 22. doi: 10.1002/ijc.29403. [Epub ahead of print]

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, Dematteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014 Aug 1;120(15):2325-33.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul 31. pii: S1470-2045(14)70330-4. doi: 10.1016/S1470-2045(14)70330-4. [Epub ahead of print]

Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M.VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.

Al-Batran SE, Werner DRecent advances and future trends in the targeted therapy of metastatic gastric cancer. Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):555-69.

Werner D*, Battmann A*, Steinmetz K, Jones T, Lamb T, Martinez M, Altmannsberger HM, Al-Batran SE. The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. Journal of Translational Medicine. (*both authors contributed equally to this study). J Transl Med. 2014 Jun 6;12:160.

Limm K, Ott C, Wallner S, Mueller DW, Oefner P, Hellerbrand C, Bosserhoff AK. Deregulation of protein methylation in melanoma Eur J Cancer. 2013 Apr;49(6):1305-13. Epub 2012 Dec 19.

Amato G, Romano G, Agrusa A, Cocorullo G, Gulotta G, Goetze T. Dynamic inguinal hernia repair with a 3d fixation-free and motion-compliant implant: a clinical study. Surg Technol Int. 2014 Mar;24:155-65.

Al-Batran SE. The role of radiation therapy for resectable adenocarcinoma of the gastroesophageal junction. Oncologist. 2014;19(4):431. doi: 10.1634/theoncologist.2013-0424.

Al-Batran SE, Geissler M, Seufferlein T, Oettle H. Nab-Paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Oncol Res Treat. 2014;37(3):128-34. doi: 10.1159/000358890. Epub 2014 Feb 7.

Goetze TO, Paolucci V. Extended cholecystectomy an underestimated prognostic factor in T1b- T3 incidental gallbladder carcinoma- Results of the German- Registry Chirurg. 2014 Feb;85(2):131-8. doi: 10.1007/s00104-013-2587-8.

Kripp M, Al-Batran SE, Rosowski J, Pauligk C, Homann N, Hartmann JT, Moehler M, Hofheinz RD. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer. 2014 Jan;17(1):181-7.

2013

Miranda MB, Hartmann JT, Al-Batran SE, Kripp M, Gencer D, Hochhaus A, Hofheinz RD, Merx K. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol. 2014 Feb 21.

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Eschbach C, Claas S, Hartmann A, Ficker JH, Jäger E, Brueckl WM. The validation of estrogen receptor 1 (ESR1) mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. Int J Cancer. 2014 May 15;134(10):2314-21.

Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E.Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J Clin Oncol. 2013 Nov 1;31(31):3935-43.

Stenholm L, Stoehlmacher-Williams J, Al-Batran SE, Heussen N, Akin S, Pauligk C, Lehmann S, Senff T, Hofheinz RD, Ehninger G, Kramer M, Goekkurt E. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol. 2013 Oct;24(10):2581-8.

Brueckl WM, Al-Batran SE, Ficker JH, Claas S, Atmaca A, Hartmann A, Rieker RJ, Wirtz RM. Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. Int J Cancer. 2013 Oct 15;133(8):1825-31.

Gutt, Carsten N. MD; Encke, Jens MD; Köninger, Jörg MD; Harnoss, Julian-Camill MD; Weigand, Kilian MD; Kipfmüller, Karl MD; Schunter, Oliver MD; Götze, Thorsten MD Golling, Markus T. MD; Menges, Markus MD; Klar, Ernst MD; Feilhauer, Katharina MD; Zoller, Wolfram G. MD; Ridwelski, Karsten MD; Ackmann, Sven MD; Baron, Alexandra MD; Schön, Michael R. MD; Seitz, Helmut K. MD; Daniel, Dietmar MSc; Stremmel, Wolfgang MD; Büchler, Markus W. MD, Acute Cholecystitis: Early Versus Delayed Cholecystectomy, A Multicenter Randomized Trial (ACDC Study, NCT00447304) Ann Surg September 2013 - Volume 258 - Issue 3 - p 385–393 doi: 10.1097/SLA.0b013e3182a1599b

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, Antonio CD, Zotto LD, Al-Batran SE, Marsoni S, Wolf M. A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. J Thorac Oncol. 2013 Aug;8(8):1091-1094.

Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013 Aug;24(8):2068-73.

Goetze TO, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique: analysis of 837 incidental gallbladder carcinomas in the German Registry. Surg Endosc. 2013 Aug;27(8):2821-8. Epub 2013 Feb 13.

Werner D*, Atmaca A*, Pauligk C, Pustowka A, Jäger E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med. 2013 Jun;2(3):325-33. (*both authors contributed equally to this study).

Bankstahl US, Görtelmeyer R. Measuring subjective complaints of attention and performance failures--development and psychometric validation in tinnitus of the self-assessment scale APSA. Health Qual Life Outcomes. 2013 May 29;11:86. doi: 10.1186/1477-7525-11-86

Al-Batran S-E, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jäger E. The Feasibility of Triple-Drug Chemotherapy Combination in Older Adult Patients with Esophagogastric Cancer: a Randomized Trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013 Mar;49(4):835-42.

Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer. 2013 Feb 5;108(2):265-70.

Gencer D, Al-Batran SE, Dada R, Hünerlitürkoglu AN, Gonnermann M, Kegel T, Scheiber H, Jordan WO, Burkholder I, Kellermann L, Hofheinz RD. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. J Cancer Res Clin Oncol. 2013 Feb;139(2):337-45.

Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative Chemotherapy with infusional 5-FU, Leucovorin and Oxaliplatin with or without Docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013 Feb 19;108(3):519-26.

2012

Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E, Al-Batran SE. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer. 2012 Nov 15;12:524. 

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012 Oct;23(10):2656-62.

Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012 Aug;23(8):1979-85.

Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz RD, Hartmann JT, Atmaca A, Altmannsberger HM, Jäger E. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 2012 Jul;23(7):1699-705.

Al-Batran SE, Hozaeel W, Jäger E. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. Onkologie. 2012;35(9):505-8.

Goetze TO, Paolucci V. The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry Surg Endosc. 2012 May;26(5):1382-9. Epub 2011 Nov 17

Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jäger E, Al-Batran SE. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer.  2012 Apr 1;130(7):1706-13.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012 Mar 28;307(12):1265-72.

Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 2012 Feb;130(3):491-6.

Bankstahl US, Elkin EP, Gebauer A, Görtelmeyer R. Validation of the THI-12 questionnaire for international use in assessing tinnitus: a multi-centre, prospective, observational study. Int J Audiol. 2012 Sep;51(9):671-7. doi: 10.3109/14992027.2011.653448. Epub 2012 Feb 20.

2011

Atmaca A, Pauligk C, Steinmetz K, Altmannsberger HM, Jäger E, Al-Batran SE. Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. Oncology. 2011;80(1-2):130-4.

Mueller DW, Bosserhoff AK. miRNAs as biomarkers and therapeutic targets in malignant melanoma. In: Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma (Current Clinical Pathology). Editor: Michael Murphy. Humana Press Inc., Springer Science+Business Media. 2011. Buchkapitel.

Gencer D, Tauchert F, Keilhauer N, Al-Batran SE, Stahl M, Oskay-Özcelik G, Hipp M, Leibbrand B, Prasnikar N, Trarbach T, Stoll C, van Kampen M, Hochhaus A, Lorenzen S, Hofheinz RD. Cancer Patients and the Internet: A Survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie. Onkologie. 2011;34(8-9):435-40.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011 Aug;22(8):1839-44.

Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011 Jul;47:1511-20.

G. Amato , G. Romano , T. Goetze , G. Salamone , A. Agrusa , G. Gulotta, V. Paolucci New mesh shape and improved implantation procedure to simplify and standardize open ventral hernia repair: a preliminary report Hernia 2011 15(6):659-65

Moehler M, Al-Batran SE, Andus T et al. German S3-guideline "Diagnosis and treatment of esophagogastric cancer". Z Gastroenterol. 2011 Apr;49(4):461-531.

Goetze TO, Paolucci V. Immediate Radical Re-Resection of Incidental T1b Gallbladder Cancer and the Problem of an Adequate Extent of Resection (Results of the German Registry "Incidental Gallbladder Cancer" Zentralbl Chir. 2011 Mar 1

Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer. 2011 Sep 1;129(5):1064-74. Epub 2011 Feb 11.

Mueller DW, Bosserhoff AK. MicroRNAs in malignant melanoma. In: Melanoma Development: Molecular Biology, Genetics and Clinical Application. Editor: Anja Bosserhoff. Springer Verlag, Wien. 2011. Buchkapitel.

Karbach J, Neumann A, Atmaca A, Wahle C, Brand K, von Boehmer L, Knuth A, Bender A, Ritter G, Old LJ, Jäger E. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res. 2011 Feb 15;17(4):861-70.

Al-Batran SE, Ruppert M, Jäger E. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report. Onkologie. 2011;34(1-2):42-5.

2010

Al-Batran SE, Güntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jäger E.  Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer. 2010 Nov 9;103(10):1518-23.

Hofheinz RD*, Al-Batran SE*, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 2010 Sep 15;16(18):4666-74. (*geteilte Erstautorenschaft)

Goetze TO, Paolucci V. Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German Registry. Surg Endosc. 2010 Sep;24(9):2156-64.

Goetze TO, Paolucci V. World J Surg. 2010 Sep;34(9):2262-3; author reply 2264-5.                                                                                                            

Hofheinz RD, Al-Batran SE, Ridwelski K, Görg C, Wehle K, Birth M, Fetscher S, Scheiber H, Lukan N, Lordick F. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie. 2010;33(10):512-8.

Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94-8.

Mueller DW, Bosserhoff AK. The evolving concept of “melano-miRs” – microRNAs in melanomagenesis. Pigment Cell Melanoma Res. 2010 Oct;23(5):620-6. Epub 2010 Jul 12.

Braig S*, Mueller DW*, Rothhammer T, Bosserhoff AK. MicroRNA miR-196a is a central regulator of HoxB7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci. 2010 Oct;67(20):3535-48. Epub 2010 May 18. *beide Autoren sind Erstautoren.

Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 1;116(11):2511-8.

Neumann A, Karbach J, Atmaca A, Jäger E. Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy. Med Klin (Munich). 2010 Apr;105(4):273-5.

2009

Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73. 

Goetze TO, Paolucci V. Use of retrieval bags in incidental gallbladder cancer cases. World J Surg. 2009 Oct;33(10):2161-5.

Müller DW, Meyer C, Gürster S, Küper U, Huber H, Rachel R, Wanner G, Wirth R, Bellack A. The Iho670 fibers of Ignicoccus hospitalis: a new type of archaeal cell surface appendage. J Bacteriol 2009 Oct ;191(20):6465-8. Epub 2009 Aug 14.

Müller DW, Bosserhoff AK. miR(acle)s – new players in the regulation of known suspects. Pigment Cell Melanoma Res2009 Oct;22(5):525-6. Epub 2009 Aug 11. News and Views Artikel.

Mueller DW, Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer. 2009 Aug 18;101(4):551-6. Epub 2009 Jul 28. Review.

Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 2009 Jul;129(7):1740-51. Epub 2009 Feb 12.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J. Pharmacogenetic Analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2009 Jun 10;27(17):2863-73.

Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, Jaeger E, Ehninger G, Stoehlmacher J. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol. 2009 Mar;20(3):481-5.

Atmaca A, Al-Batran SE, Neumann A, Kolassa Y, Jäger D, Knuth A, Jäger E. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study. Gynecol Oncol. 2009 Feb;112(2):384-8.

Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009 Jan 13;100(1):44-9.

Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):58-61.

2008

Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) is Active and has a Favorable Safety Profile for Patients with Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction: a Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov;19(11):1882-7. 

Müller DW, Bosserhoff AK. Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma. Oncogene. 2008 Nov 6;27(52):6698-706. Epub 2008 Aug 4.

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442, 2008.

Burghardt T, Saller M, Gürster S, Müller D, Meyer C, Jahn U, Hochmuth E, Deutzmann R, Siedler F, Babinger P, Wirth R, Huber H, Rachel R. Insight into the proteome of the hyperthermophilic Crenarchaeon Ignicoccus hospitalis: the major cytosolic and membrane proteins. Arch Microbiol. 2008 Sep;190(3):379-94. Epub 2008 Jun 27.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J. Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

Wedel SA, Sparatore A, Del Soldato P, Al-Batran SE, Atmaca A, Juengel E, Hudak L, Jonas D, Blaheta RA. New Histone Deacetylase Inhibitors As Potential Therapeutic Tools For Advanced Prostate Carcinoma. J Cell Mol Med. 2008 Dec;12(6A):2457-66.

Lordick F, Ridwelski K, Al-Batran SE, Trarbach T, Schlag PM, Piso P. Treatment of gastric cancer. Onkologie. 2008;31 Suppl 5:32-9.

Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT.Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.Onkologie. 2008 May;31(5):271-81.

Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry. Surg Endosc. 2008 Feb 5; 

Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg. 2008 Jan;247(1):104-8. 

2007

Al-Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C, Düx M, Izbicki JR, Kraus T, Fischer T, Jäger E. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer. 2007;10(3):145-522006.

Al-Batran SE , Atmaca A , Schleyer E , Pauligk C, Hosius C , Ehninger G , Jäger E. Imatinib Mesylate for Targeting the Platelet-derived Growth Factor Beta-receptor (PDGFR-ß) in Combination with Fluorouracil and Leucovorin in Patients with Refractory Pancreatic, Bile Duct, Colorectal, or Gastric Cancer - a Dose Escalation Phase I Trial. Cancer 2007 May 1;109(9):1897-904.

Al-Batran SE,  Kerber A, Atmaca A, Dechow C, Reitsamer E,  Schmidt S,  Kolassa Y, Neumann A,  Weidmann E, Hartmann JT,  Jäger E. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie. 2007 Feb;30(1-2):29-34.

Kretzschmar A, Wiege T, Al-Batran SE, Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger G. Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther. 2007 Sep 1;4(4):203-10.

Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007 Oct 19;7:16.

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E.Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007 Jul 16;97(2):177-82.

Hartmann JT, Pintoffl JP, Al-Batran SE, Quietzsch D, Meisinger I, Horger M, Nehls O, Bokemeyer C, Königsrainer A, Jäger E, Kanz L. Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. Onkologie 2007 May;30(5):235-40.

Höhler T, Rödel C, Hölscher AH, Al-Batran SE. Neoadjuvante und palliative Therapie des Osophagus- und Magenkarzinoms.  Onkologie 2007; 30 Suppl 2 :23-26.

Al-Batran SE, Scholz M, Jäger E. Chemotherapy for Advanced Gastric Cancer.   J Clin Oncol 2007 Feb 20;25(6):729.

Karbach J, Gnjatic S, Pauligk C, Bender A, Maeurer M, Schultze JL, Nadler K, Wahle C, Knuth A, Old LJ, Jäger E. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer. 2007 Nov 1;121(9):2042-8.

2006

Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jäger E. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006 Jun 5; 94(11):1615-20.

Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jäger E. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70(2):141-6.

Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 2010 Sep 15;16(18):4666-74. doi: 10.1158/1078-0432.CCR-10-0318. Epub 2010 Aug 3.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.

Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother. 2006 Aug;18(4):415-20.

Goetze T, Paolucci V. Does laparoscopy worsen the prognosis for incidental gallbladder cancer? Surg Endosc. 2006 Feb;20(2):286-93.

2005

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005, 65(9):3937-41.

Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU,  Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma.  J Clin Oncol 2005, 2:3383-9.

Von Minckwitz G, Harder S, Hovelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jager D, Maurer AB, Wels WS. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7(5):R617-26.

Wolschke C, Goekkurt E, Al-Batran SE, Hossfeld DK, Stoehlmacher J. Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer - report of 2 cases. Onkologie, 2005, 28(11):589-92.

Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jäger E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 2005 Dec 12;5:11.

2004

Al-Batran S, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel JM, Seipelt G, Rost A, Orth J, Knuth J, Jäger E. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004, 15;22(4):658-63. 

Al-Batran S, Atmaca A, Bert F, Jäger D, Frisch C, Neumann A, Orth J, Knuth A, Jäger E. Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pre-treated Patients with Metastatic Lung Cancer. Onkologie 2004, 27(6):534-8.

Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke HJ, Pfluger KH, Al-Batran SE, Buchele T, Hofheinz RD, Kanz L, Bokemeyer C. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anti-cancer Drugs 2004, 15(5):473-7.

Pauligk C, Nain M, Reiling N, Gemsa D, Kaufmann A. CD14 is required for influenza A virus-induced cytokine and chemokine production. Immunobiology. 2004;209(1-2):3-10.

V. Paolucci,  T. Götze. Prognose des okkulten Gallenblasenkarzinoms nach laparoskopischer und konventioneller Cholezystektomie. Chirurgisches Forum 2004 für experimentelle und klinische Forschung (Forumband 33)

2003

Hofheinz RD, Al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003, 26(1):44-8.

Paolucci V, Neckell M, Gotze T. [Unsuspected Gallbladder carcinoma - The CAE-S/CAMIC registry] Zentralbl Chir. 2003 Apr;128(4):309-12.

2002

Gamarra F, Wagner S, Al-Batran S, Maier I, Castro M, Hautmann H, Bergner A, Baumgartner R, and Huber RM. Kinetics of 5-aminolevulinic acid-induced fluorescence in organ cultures of bronchial epithelium and tumor. Respiration 2002, 69(5):445-50.

Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.  Cancer Immun. 2002 Sep 19;2:12.

Jäger D, Stockert E, Karbach J, Herrlinger K, Atmaca A, Arand M, Chen YT, Gnjatic S, Old LJ, Knuth A, Jäger E. Urine antibody against human cancer antigen NY-ESO-1.  Cancer Immun. 2002 Aug 6;2:10.

2001

Kaufmann A, Salentin R, Meyer RG, Bussfeld D, Pauligk C, Fesq H, Hofmann P, Nain M, Gemsa D, Sprenger H. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology. 2001 Dec;204(5):603-13. Review.

1999

Al-Batran S, Astner ST, Supthut M, Gamarra F, Brueckner K, Welsch U, Knuechel R, Huber RM. Three-dimensional in vitro cocultivation of lung carcinoma cells with human bronchial organ culture as a model for bronchial carcinoma. Am J Respir Cell Mol Biol 1999, 21:200-8. 

1995

Dengler R, Münstermann U, Al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B. Immuncytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 1995, 89:250-57.